Jun. 9 at 2:06 PM
$NUVL M&A revenue multiples v. peer pre-commercial stage M&A (with active PDUFAs) plus 5 commercial-stage bios acquired very shortly post FDA approval.
$ACLX is included as a peer
Using NUVL's 3/31/2026 Cap Table, we get a fully diluted enterprise value of
$9.383B or call it
$9.4B (calculation attached that reconciles to the
$10.6B market cap per NUVL press release).
NUVL Year 1 - 10 = FY2027 - FY2036 analyst consensus per Seeking Alpha. The peer transactions take year 1 - 10 per the acquiree management. We will update this analysis when NUVL files their 14D9 with the SEC in about 4 weeks
The attached analysis (that has not been verified) suggests NUVL is being acquired at one of the highest revenue multiples in this peer group (assuming analyst consensus is more or less accurate.
Investors in
$RVMD &
$CELC may want to review. This is not investment advice
$CLDX
